Strata Skin Sciences’ Xtrac Momentum 1.0 Device Receives Japanese Approval
Overview
Strata Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the approval of its XTRAC Momentum 1.0 device by the Ministry of Health, Labor and Welfare of Japan. The company initially launched the XTRAC Momentum in the US in early 2022. The immediate commercial rollout of the device in Japan will be through JMEC Co., Ltd., the company’s longstanding Japanese strategic partner and distributor. Strata’s excimer devices are currently used by over 300 hospitals and private practice dermatology clinics in Japan.
Words from CEO: Strata
“With this regulatory approval, we are now able to offer the Momentum device -- our most advanced excimer laser -- into the Japanese dermatology market. Working with JMEC, we look forward to introducing doctors and patients to the benefits of Momentum for the treatment of various dermatology conditions, such as psoriasis, eczema, and vitiligo,” commented Strata’s president and CEO Dr. Dolev Rafaeli.
XTRAC Excimer Laser Technology
The company’s XTRAC excimer laser technology allows for the precise delivery of targeted UVB light therapy to specific treatment areas of the skin, for both adult and paediatric patients suffering from inflammatory skin conditions such as psoriasis, atopic dermatitis, and vitiligo.
The new XTRAC Momentum 1.0 represents the latest in excimer laser technology and delivers higher power and a faster repetition rate than the current models.
The Momentum also offers a new user interface and slim design, both intended to improve the treatment experience.
Strata Skin Sciences
Strata Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne.